Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: A Danish, population-based, 6-year follow-up study

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 136-144

  Lohse, Nicolai ^a,b   Kronborg, Gitte ^c   Gerstoft, Jan ^d   Larsen, Carsten Schade ^e   Pedersen, Gitte ^f   Pedersen, Court ^a,b   Sørensen, Henrik Toft ^e,g   Obel, Niels ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; DENMARK; DISEASE CONTROL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TREATMENT FAILURE; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; VIRAL LOAD;

EID: 29244449843     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498515     Document Type: Article

References (33)

1. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA Study. Lancet 2000; 356:291-6.
2. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS 1999; 13:943-50.
3. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
4. Palella Jr FJ, Chmiel JS, Moorman AC, Holmberg SD. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-26.
5. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low Mortality in HIV-infected patients starting HAART in advance of immunological deterioration: a comparison with the general population. AIDS 2004; 18: 89-97.
6. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-86.
7. Ormaasen V, Bruun JN, Sandvik L, Holberg-Petersen M, Gaarder PI. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection. Scand J Infect Dis 2003; 35: 383-8.
8. + cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-64.
9. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis 2002; 185:178-87.
10. Perneger TV, Abrahamowicz M, Bartlett G, Yerly S. Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV Cohort Study. J Investig Med 2000; 48:207-12.
11. Miller V, Phillips AN, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-97.
12. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4(Suppl 1):1-41.
13. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003; 17(Suppl 2):S3-26.
14. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-15.
15. Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003; 17:2345-9.
16. Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-9.
17. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
18. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
19. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-77.
20. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological, and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000; 14:1545-52.
21. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
22. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137:381-433.
23. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37:1112-8.
24. Egger M, Chene G, Sterne JA, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-86.
25. Jensen-Fangel S, Pedersen C, Larsen CS, Tauris P, Møller A, Obel N. Changing demographics in an HIV-infected population: results from an observational cohort study in Western Denmark. Scand J Infect Dis 2001; 33:765-70.
26. Lohse N, Hansen AB, Jensen-Fangel S, et al. Demographics of HIV-1 infection in Denmark: results from The Danish HIV Cohort Study. Scand J Infect Dis 2005; 37:338-43.
27. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79:340-9.
28. The SMART Study. Available at: http://www.smart-trial.org. Accessed 14 November 2005.
29. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 2001; 286:171-9.
30. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/mL. AIDS 2002; 16:1521-7.
31. Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28:105-13.
32. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-29.
33. Percus JK, Percus OE, Markowitz M, Ho DD, Di Mascio M, Perelson AS. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol 2003; 65:263-77.